Pretargeted Radioimmunotherapy of Colorectal Cancer: A Phase I Study to Determine Dose-limiting Toxicity and Maximum Tolerated Dose of an Anti-CEACAM5 bsMAb-pretargeted 90Y-hapten-peptide.
Phase of Trial: Phase I
Latest Information Update: 24 Sep 2012
At a glance
- Drugs TF 2 (Primary) ; Indium-111-IMP 288
- Indications Colorectal cancer
- Focus Adverse reactions
- 24 Sep 2012 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
- 18 Jan 2011 New trial record